FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361285518> ?p ?o ?g. }

• W4361285518 abstract "Recently, several researchers have reported the incidence of cardiac-related toxicities occurring with nivolumab (Opdivo) and pembrolizumab (Keytruda). There is still a need for balance between oncology treatment efficacy and reduction of cardiotoxicity burden in immune checkpoint inhibitor (ICI)-treated patients. Thus, the primary aim was to determine whether pembrolizumab or nivolumab would present with a greater risk for cardiotoxicity reports.This meta-analysis was performed with respect to the MOOSE reporting guidelines. Studies were retrieved by searching PubMed, Embase, and Google Scholar; the search terms were Keytruda or Pembrolizumab, PD1 inhibitors, anti-PD1 drugs, Nivolumab or Opdivo, and cardiotoxicities or cardiac toxicity. The study was restricted to original articles investigating ICI-induced cardiac immune-related adverse events (irAEs). The targeted population was cancer patients treated with either pembrolizumab or nivolumab monotherapy, of which those with records of any cardiac events following the therapy were labeled as events. The measures used to achieve the comparison were descriptive proportions, probabilities, and meta-analysis pooled odds ratios (ORs).Fifteen studies were included in this meta-analysis. Nivolumab accounted for 55.7% cardiotoxicity and pembrolizumab, for 27.31% (P = 0.027). The meta-analysis was based on the Mantel-Haenszel method, and the random-effect model yielded a pooled OR = 0.73 (95% CI [0.43-1.23] P = 0.24), with considerable heterogeneity (I2 = 99% P = 0). Hence, the difference in cardiotoxicity odds risk between pembrolizumab and nivolumab was not statistically significant. On subgroup analysis based on cardiotoxicity type, the myocarditis subgroup in which there was no statistical heterogeneity was associated with a significant cardiotoxicity risk increase with pembrolizumab (OR = 1.30 [1.07;1.59], P< 0.05; I2 = 0%, Ph = 0.4).To our knowledge, this is the first meta-analysis to compare the cardiotoxicity potentials of nivolumab and pembrolizumab. In contrast to previous reports, the overall findings here demonstrated that nivolumab-induced cardiotoxicity was more commonly reported in the literature than pembrolizumab; however, myocarditis seemed more likely to occur with pembrolizumab therapy." @default.
• W4361285518 created "2023-03-31" @default.
• W4361285518 creator A5014940331 @default.
• W4361285518 creator A5031003036 @default.
• W4361285518 creator A5064244805 @default.
• W4361285518 date "2023-03-29" @default.
• W4361285518 modified "2023-10-01" @default.
• W4361285518 title "Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis" @default.
• W4361285518 cites W1979423827 @default.
• W4361285518 cites W2094366129 @default.
• W4361285518 cites W2130865996 @default.
• W4361285518 cites W2158299492 @default.
• W4361285518 cites W2167824481 @default.
• W4361285518 cites W2265285917 @default.
• W4361285518 cites W2346275821 @default.
• W4361285518 cites W2376844206 @default.
• W4361285518 cites W2519380942 @default.
• W4361285518 cites W2588681363 @default.
• W4361285518 cites W2624988838 @default.
• W4361285518 cites W2637316398 @default.
• W4361285518 cites W2734836464 @default.
• W4361285518 cites W2789315292 @default.
• W4361285518 cites W2791483720 @default.
• W4361285518 cites W2809173583 @default.
• W4361285518 cites W2885900087 @default.
• W4361285518 cites W2891486030 @default.
• W4361285518 cites W2903686952 @default.
• W4361285518 cites W2921474571 @default.
• W4361285518 cites W2924782035 @default.
• W4361285518 cites W2940307359 @default.
• W4361285518 cites W2940759533 @default.
• W4361285518 cites W2945590213 @default.
• W4361285518 cites W2955663214 @default.
• W4361285518 cites W2995355574 @default.
• W4361285518 cites W2996106071 @default.
• W4361285518 cites W3002425056 @default.
• W4361285518 cites W3003854411 @default.
• W4361285518 cites W3023745224 @default.
• W4361285518 cites W3026324639 @default.
• W4361285518 cites W3032537130 @default.
• W4361285518 cites W3035065225 @default.
• W4361285518 cites W3035626072 @default.
• W4361285518 cites W3047367404 @default.
• W4361285518 cites W3082287626 @default.
• W4361285518 cites W3084285067 @default.
• W4361285518 cites W3088867352 @default.
• W4361285518 cites W3090540823 @default.
• W4361285518 cites W3110800814 @default.
• W4361285518 cites W3129286475 @default.
• W4361285518 cites W3139404557 @default.
• W4361285518 cites W3153302452 @default.
• W4361285518 cites W3168226229 @default.
• W4361285518 cites W3176930255 @default.
• W4361285518 cites W3198735776 @default.
• W4361285518 cites W3206017423 @default.
• W4361285518 cites W3212242216 @default.
• W4361285518 cites W4211223138 @default.
• W4361285518 cites W4213324404 @default.
• W4361285518 cites W4220725472 @default.
• W4361285518 doi "https://doi.org/10.3389/fonc.2023.1080998" @default.
• W4361285518 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37064101" @default.
• W4361285518 hasPublicationYear "2023" @default.
• W4361285518 type Work @default.
• W4361285518 citedByCount "0" @default.
• W4361285518 crossrefType "journal-article" @default.
• W4361285518 hasAuthorship W4361285518A5014940331 @default.
• W4361285518 hasAuthorship W4361285518A5031003036 @default.
• W4361285518 hasAuthorship W4361285518A5064244805 @default.
• W4361285518 hasBestOaLocation W43612855181 @default.
• W4361285518 hasConcept C121608353 @default.
• W4361285518 hasConcept C126322002 @default.
• W4361285518 hasConcept C143998085 @default.
• W4361285518 hasConcept C156957248 @default.
• W4361285518 hasConcept C197934379 @default.
• W4361285518 hasConcept C2776694085 @default.
• W4361285518 hasConcept C2777701055 @default.
• W4361285518 hasConcept C2778233292 @default.
• W4361285518 hasConcept C2780030458 @default.
• W4361285518 hasConcept C2780057760 @default.
• W4361285518 hasConcept C2908647359 @default.
• W4361285518 hasConcept C71924100 @default.
• W4361285518 hasConcept C95190672 @default.
• W4361285518 hasConcept C99454951 @default.
• W4361285518 hasConceptScore W4361285518C121608353 @default.
• W4361285518 hasConceptScore W4361285518C126322002 @default.
• W4361285518 hasConceptScore W4361285518C143998085 @default.
• W4361285518 hasConceptScore W4361285518C156957248 @default.
• W4361285518 hasConceptScore W4361285518C197934379 @default.
• W4361285518 hasConceptScore W4361285518C2776694085 @default.
• W4361285518 hasConceptScore W4361285518C2777701055 @default.
• W4361285518 hasConceptScore W4361285518C2778233292 @default.
• W4361285518 hasConceptScore W4361285518C2780030458 @default.
• W4361285518 hasConceptScore W4361285518C2780057760 @default.
• W4361285518 hasConceptScore W4361285518C2908647359 @default.
• W4361285518 hasConceptScore W4361285518C71924100 @default.
• W4361285518 hasConceptScore W4361285518C95190672 @default.
• W4361285518 hasConceptScore W4361285518C99454951 @default.
• W4361285518 hasLocation W43612855181 @default.
• W4361285518 hasLocation W43612855182 @default.
• W4361285518 hasLocation W43612855183 @default.

• next